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The rationale for identifying drug targetswithinhelminthneuromuscular signalling systems is based on the
premise that adequate nerve andmuscle function is essential formany of the key behavioural determinants
of helminth parasitism, including sensory perception/host location, invasion, locomotion/orientation,
attachment, feeding and reproduction. This premise is validated by the tendency of current anthelmintics
to act on classical neurotransmitter-gated ion channels present on helminth nerve and/or muscle, yielding
therapeutic endpoints associated with paralysis and/or death. Supplementary to classical neurotransmit-
ters, helminth nervous systems are peptide-rich and encompass associated biosynthetic and signal trans-
duction components – putative drug targets that remain to be exploited by anthelmintic chemotherapy. At
this time, no neuropeptide system-targeting lead compounds have been reported, and given that our basic
knowledge of neuropeptide biology in parasitic helminths remains inadequate, the short-term prospects
for such drugs remain poor. Here, we review current knowledge of neuropeptide signalling in Nematoda
and Platyhelminthes, and highlight a suite of 19 protein families that yield deleterious phenotypes in
helminth reverse genetics screens. We suggest that orthologues of some of these peptidergic signalling
components represent appealing therapeutic targets in parasitic helminths.
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Parasitic helminths (worms classiﬁed in phyla Nematoda and
Platyhelminthes) remain an insidious threat to humanhealth, social
development and economic progress worldwide. Infections by par-
asitic nematodes andﬂatwormshave direct effects on humanhealth
andwell being throughout thedevelopingworld and are responsible
for a large proportion of the so-called ‘Neglected Tropical Diseases’
(Hotez et al., 2008). Additionally, helminths maintain an economic
grip on the worldwide agricultural economy, a situation
compoundedby the spread of anthelmintic-resistance. For example,
nematodes displaying multidrug-resistance to all of the well-
established therapeutic compounds threaten the sustainability of
livestock farming in some areas of South America, South Africa,
Malaysia, New Zealand and the USA (Kaplan, 2004; Sutherland and
Leathwick, 2011). Ruminant farming worldwide is threatened fur-
ther by Fasciola spp. liver ﬂukes, which have displayed incidences
of resistance to triclabendazole, the singlemost effective fasciolicide
on themarket (Keiser andUtzinger, 2007). The latter issue illustrates
a salient point in anthelmintic therapy–wehaveonly a limited arse-
nal of drugswithwhich to combatpathogenichelminths and, partic-
ularly in human infections,many of the drugs in use are sub-optimal
and suffer from our poor understanding of their pharmacology
(Geary et al., 2010). Clearly, new anthelmintic treatment regimens
will be essential in the short to medium term.
The development of resistance to chemotherapeutics is inevita-
ble. However, while novel non-chemical control alternatives have
been suggested (Hoste and Torres-Acosta, 2011), and given the
limited availability of helminth vaccines (Hotez et al., 2010), the
intelligent and sustainable use of available anthelmintics remains
our best short term option for helminth control (Kaplan, 2004).
While a few new drug classes active against nematodes (cyclo-
octadepsipeptide/emodepside, Harder et al. (2003); paraherqua-
mide, Lee et al. (2002); aminoacetonitrile derivatives [AADs],
Ducray et al. (2008)) are showing promise and progress has been
reported for some new trematocidal drugs (Sayed et al., 2008;
Keiser et al., 2010), to rely on these novel compounds/leads to
the detriment of continued anthelmintic discovery would be to
ignore the lessons of the past.
Modern drug discovery paradigms rely largely on mechanism-
based screening of compounds against heterologously-expressed
targets, which have been selected on the basis of biology, distinct
host/pathogen pharmacology and ‘druggability’ (i.e. that the pro-
tein family in question is already targeted by existing drugs)
(Geary et al., 1999). The quality of evidence required to support
this target selection has increased as a factor of the economic
and socio-political pressures experienced by the pharmaceutical
industry (Knowles and Gromo, 2002; Geary et al., 2004), which at-
tempts to discover new drugs for which proﬁtability is a primary
consideration. As such, the rationale for selecting a target must
be strongly supported by evidence from basic research.
Our own interests in parasite neuropeptides evolved through
the pioneering work of David W. Halton and Chris Shaw in the
mid 1980s (see Halton et al., 1992, 1994) and progressed through
neuropeptide localisation (Halton, 2004), characterisation (Maule
et al., 1991, 1993; Marks et al., 1999) and physiology (Maule
et al., 1995, 1996a,b, 2002) phases, prior to a slowing of impetus
as classic approaches went out of vogue and genomic/post-geno-
mic technologies captured attention. Recently, parasite neuropep-
tide research has been reinvigorated by two developments: the
accumulation of transcriptomic/genomic resources for parasites
(McVeigh et al., 2005a, 2008, 2009; see reviews by McVeigh
et al., 2006; Marks and Maule, 2010; Mousley et al., 2010); and,
the potential of RNA interference (RNAi) to facilitate gene function
studies in parasites (Hussein et al., 2002; Urwin et al., 2002; Boyleet al., 2003; Skelly et al., 2003; Kimber et al., 2007; McGonigle
et al., 2008; Pierson et al., 2010; Dalzell et al., 2011).
Whilst neuropeptide research continues to seed our under-
standing of parasite neurobiology, it also facilitates the identiﬁca-
tion and validation of candidate anthelmintic targets (e.g. Mair
et al., 2004; Atkinson et al., 2010; Dalzell et al, 2010; Novozhilova
et al., 2010; McVeigh et al., 2011). Targets originating from hel-
minth neuropeptidergic signalling systems have generated inter-
mittent interest from some of the major players in animal health
drug discovery since the early 1990s. The target potential of hel-
minth neuropeptidergic systems was recognised in particular by
the successive Upjohn/Pharmacia and Pharmacia/Pﬁzer companies,
where the animal health drug discovery research teams, initially
led by Timothy G. Geary and David P. Thompson, generated signif-
icant amounts of valuable data on the basic structure, function and
pharmacology of helminth neuropeptides and receptors (for re-
views see Geary et al., 1992, 1995; Thompson et al., 1996; Green-
wood et al., 2005; Geary and Kubiak, 2005). Since then, industry
efforts in these areas appear to have waned. Here, we review cur-
rent knowledge of helminth neuropeptide signalling mechanisms,
and examine the evidence for drug target candidates within these
pathways, including the receptors responsible for neuropeptide
biological activity, and the enzymes involved in peptide synthesis,
signal transduction and signal termination. We consider evidence
from reverse genetics and RNAi experiments in parasites and mod-
el organisms, and whether existing inhibitors or drugs against each
protein family are already in use. Also, we have attempted to illus-
trate those areas where further study is warranted.2. Criteria for drug target selection and validation
It is well known that a large proportion of the anthelmintics used
to control parasitic worms act on targets associated with themodu-
lation of nerve and/or muscle systems and that these systems are
pivotal to motor and sensory capabilities (Martin and Robertson,
2010). This is most evident amongst the compounds used for nema-
tode parasite control and encompasses both long established drugs
including dichlorovos, levamisole, morantel, piperazine, pyrantel
and the macrocyclic lactones, and more recent additions to the
anthelmintic arsenal such as the cyclooctadepsipeptides, paraher-
quamides andAADs. The empirical natureof anthelmintic discovery,
at least to this point, largely dispels the potential of experimental
prejudice having selected for neuro/myo-modulatory drugs, leaving
us to ponder the preferential selection of parasite nerve/muscle tar-
getsby empirical drug screeningprocesses. Although theseanti-par-
asite drug screens were of empirical design, we cannot discount the
possibility of bias inherent to the chemical libraries screened, and
the obvious appeal of paralysis (ﬂaccid or spastic) as a phenotypic
endpoint, combining to skew the selection towards nerve/muscle
targets. Nevertheless, it seems very unlikely that these alone could
explain the propensity of frontline anthelmintics to act on targets
associated with parasite nerve/muscle – especially as this marked
bias is not as apparent amongst the platyhelminth-targeting anthel-
mintics. Therefore, a clear take home message from these observa-
tions is that parasite neuromuscular systems are lucrative for drug
target discoverywithmuch evidence thatmultiple targets from this
resource are druggable.With front-line anthelmintics, much lauded
for their efﬁcacy and spectrum, facing the constant threat of resis-
tance, we must consider sources of new targets that could facilitate
the continued discovery of new drugs and so safeguard the future of
helminth parasite chemotherapy.
The evolving strategies and changing pressures/expectations
within the pharmaceutical sector demands mechanism-based ap-
proaches to drug discovery and strong, current market drivers,
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threat) in key host species and geographical regions to justify
investment being channelled to anthelmintic discovery/develop-
ment programmes. The mechanism-based approaches to drug dis-
covery dictate that we mine for new targets and initiate their
validation prior to screen implementation. Although helminth par-
asites have been late entrants to the genomics/transcriptomics era,
they have well and truly arrived such that we have the luxury of
rapidly expanding resources from which to select targets for vali-
dation. This late deluge of resources has exposed the absence of
functional genomics tools for many/most parasites. Although
RNA interference (RNAi) has facilitated reverse genetic studies in
distinct parasite species (Hussein et al., 2002; Urwin et al., 2002;
Boyle et al., 2003; Skelly et al., 2003; McGonigle et al., 2008;
Pierson et al., 2010), it is still a developing platform and not yet
robust enough to drive post-genomic screens that would validate
targets in the absence of volume ﬁlters that focus efforts on small
sub-sets of parasite genes. Therefore, before the initiation of
validation processes we are thrust back to the position of having
to make selections based on such criteria as target function/impor-
tance and ‘druggability’ in other (model) species, criteria that can
be provided to support a huge array of parasite gene sets by
scientists’ enthusiastic about their individual merits.
Whilst pre-experimental validation processes claim rigour, they
often rely on the assumption of functional conservation in target
parasite and model species. Further, by their design, they unavoid-
ably bias selections to those targets present in free-living, model
species, leading to the relative neglect of molecules involved in
host-parasite interplay. Weaknesses aside, initial target selections
are founded on both biological and theoretical justiﬁcations prior
to functional validation. At this time, the latter is constrained by
the lack of available and rigorous functional validation tools.
There are a number of broad criteria that are commonly used to
drive target selection processes, although the relative importance
of each can vary with need and is open to debate. Below is a list
of the most common criteria used to provide preliminary and
experimental validations for parasite drug targets.
2.1. Criteria for anthelmintic target candidature
(i) Druggability of drug target candidate
(a) Existing drugs act on homologous targets in other phyla,
i.e. target family is already known to be ‘druggable’ in
other systems. This may facilitate pre-selection of drug
libraries/chemistries to be screened, diminishing size of
initial screening efforts.
(b) Drug target candidate is known to be amenable to heter-
ologous expression; an obvious route to medium/high
throughput screening is desirable.(ii) Expression/occurrence of drug target candidate
(c) Drug target candidate is expressed in key parasite species
forwhich control issues are a current or potential concern.
(d) Drug target candidate is expressed in key life stage(s) of
parasite that are amenable to chemotherapy.
(iii) Resistance, spectrum and toxicity of drug target candidate(e) Drug target candidate is new, i.e. it is not known to inter-
act with available anthelmintics.
(f) Drug target candidate is unique to the parasite and does
not occur in the host; in the case of orthologues occur-
ring in both parasite and host, the candidate drug target
must display structural differences from host protein(s).
(g) Evidence that drug target candidate is well conserved
across multiple parasite species, potentially facilitating
broad spectrum action of drug leads. A non-conserved
drug target candidate may warrant selection where tar-
get species merit investment in selective drugs.(iv) Function of drug target candidate
(h) Experimental evidence of functional importance to para-
site, i.e. deleterious effects of either over- or under-
expression of target protein; in the absence of functional
data from parasite, evidence of functional importance in
other (preferably related/model) species. It may be
acceptable to move forward with strong theoretical sup-
port for functional importance. Obviously, evidence of
critical function in parasite is needed at some stage.With these criteria in mind, we now consider the selection of
neuropeptide signalling processes as a key resource for parasite
drug targets.3. Do helminth neuropeptidergic signalling proteins represent
good drug targets?
Firstly, and with respect to the ﬁrst broad selection criterion of
druggability, we know that nerve/muscle function has provided
many of the most useful targets for broad spectrum anti-parasite
chemotherapeutics. This observation extends beyond anthelmin-
tics to encompass some of the leading nematicides, such as the car-
bamate aldicarb (Baron, 1994), used to control plant parasitic
nematodes through the inhibition of acetylcholinesterase (AChE),
the enzyme responsible for the hydrolysis of the classical neuro-
transmitter acetylcholine (ACh). Although most evidence support-
ing nerve/muscle function as a target for parasite control derives
from nematodes, praziquantel, used to control schistosomes and
many tapeworms, provides evidence that this target system has
validity in ﬂatworm parasites (Pax et al., 1978). Therefore, taken
in toto, the parasite neuromuscular system is eminently ‘drugga-
ble’. However, this does not mean that all proteins associated with
signalling mechanisms within parasite neuromusculature have
equal merit and/or are equally druggable – so whilst this can be
used to support the selection of these tissue types as sources of po-
tential drug targets, it cannot be used to vindicate the selection of
individual proteins in the absence of additional justiﬁcation.
Accepting the broad notion that parasite neuromuscular sys-
tems could continue to provide opportunities for novel drug target
discovery, what are the targets we know of that have additional
attributes which promote their selection? Since most of the cur-
rent anthelmintic targets drawn from this system are ion channels
that are gated by classical neurotransmitters such as ACh, c-amino-
butyric acid (GABA) and glutamate, then other ion channels associ-
ated with classical transmitter signalling would seem obvious as
putative drug targets that await individual validation. Whilst past
success would place ligand-gated ion channels ﬁrmly at the head
of the queue of putative targets for progression to validatory
screens, there are some impediments to their selection as drug tar-
get candidates. For example, performing biological studies on these
channels is a major challenge and often requires highly skilled
physiologists to work through single cell or cell patch-based elec-
trophysiology experiments to derive data on protein functionality
(Robertson et al., 2008; Williamson et al., 2009). A key issue is that
these channels are generated through the accumulation of multi-
ple, and often inter-changeable, proteins (channel subunits), pro-
viding for channel complexity and heterogeneity (Martin et al.,
1998). This channel heterogeneity makes it difﬁcult to evaluate
which conformations of channel are functional (and important)
within parasites. Even if this is determined, reconﬁguring the rele-
vant stoichiometries in heterologous expression systems suitable
for high throughout screens remains a challenge, as described in
the case of nicotinic acetylcholine receptors (nAChRs) (Boulin
et al., 2008; Boulin et al., 2011). Further, such heterogeneity in
the protein complements of ion channels seeds concern that
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Darwinian-based progression towards resistance. Finally, for those
making decisions on funding new drug discovery programmes, the
selection of ion channels as targets raises the concern that resis-
tance against drugs acting at similar targets is already undermin-
ing control such that the search for drugs guaranteed to have a
novel mode-of-action would seem preferable. The latter approach
should diminish the risk that parasites resistant to established
anthelmintics would be resistant to new drug leads. This thinking
does assume that the established drug resistance is due to muta-
tion in the target protein rather than a more generic mechanism,
for example, enhanced detoxiﬁcation processes. Regardless, all
lead compounds are tested against known anthelmintic resistant
isolates at an early stage in development.
Whilst the targets of current anthelmintics centre upon classical
neurotransmitter signalling, neuropeptide signalling is a similarly
major, but neglected component of all helminth nervous systems.
Numerous features of neuropeptide signalling can be used to pro-
vide justiﬁcation for its selection as a drug target resource. Obvi-
ously, peptides themselves are not useful as chemotherapeutic
targets, although their transcripts could have merit as targets for
transgenic plant-based RNAi-approaches to nematode control
(Huang et al., 2006; Yadav et al., 2006; Kimber et al., 2007). Nar-
rowing focus to subsets of putative chemotherapeutic targets with-
in neuromuscular signalling, the G-protein coupled receptors
(GPCRs) step forward as proteins that are highly ‘druggable’ with
estimates that up to 50% of human medicines are directed at these
proteins (Flower, 1999; Wise et al., 2002; Jacoby et al., 2006; Ove-
rington et al., 2006; Lagerström and Schiöth, 2008). GPCRs have
well established utility as drug targets, being suitable for heterolo-
gous expression and high throughput screening. Further, helminth
GPCRs are documented as being amenable to heterologous expres-
sion (Bouchard et al., 2003; Kubiak et al., 2003, 2008; Rogers et al.,
2003; Geary and Kubiak, 2005; Greenwood et al., 2005; Mertens
et al., 2004, 2005, 2006; Carre-Pierrat et al., 2006; Omar et al.,
2007; Kimber et al., 2009; Taman and Ribeiro, 2009, 2011), mean-
ing that parasite GPCRs would meet the ﬁrst two ‘druggability’ cri-
teria. The ‘druggability’ of other candidate proteins would have to
be considered on a case-by-case basis.
With a provisional selection of GPCRs as candidate drug targets,
and following our scheme for selection, we would next consider
their expression/occurrence within key parasite species and life
stages. Unfortunately, detailed information on neuropeptide GPCR
expression in helminth parasites is lacking, thus the selection of
individual receptors would have to be justiﬁed based on initial evi-
dence derived for homologues from model species such as Caeno-
rhabditis elegans. In the absence of appropriate expression data
for parasites, data on the occurrence and activity of neuropeptides
(receptor ligands) does provide some evidence of receptor expres-
sion. An appealing feature of this widespread expression is target
accessibility to drug. Whilst widespread/high expression might re-
quire higher effective concentrations in order to affect a sufﬁcient
portion of the receptor population to have a deleterious effect,
requirements for drug penetrance (and potentially effective con-
centration) could be lower for targets that are expressed adjacent
to the surface of the parasite. Further, there is ample evidence from
physiology studies and some RNAi-based studies that neuropep-
tides modulate parasite motor function and that these receptors
are expressed on nerve and muscle tissues across key parasite life
stages (see Day et al., 1994; Maule et al., 1995, 2002; Moffett et al.,
2003; Kimber et al., 2007; Marks and Maule, 2010; Mousley et al.,
2010). Determining expression in the target life stage(s) of para-
sites is a pre-requisite for target selection and progression such
that it needs to be established at an early stage.
With respect to resistance, spectrum and toxicity, targets asso-
ciated with parasite neuropeptide signalling appear to fulﬁll theselection criteria. Firstly, no available anthelmintics are known to
target neuropeptide signalling such that drugs acting on targets
drawn from this protein subset have an a priori claim to a novel
mode-of-action. Secondly, several BLAST surveys on neuropeptide
complements have revealed marked conservation of peptide li-
gands across nematode parasite species and clades (see McVeigh
et al., 2005a, 2008). The ability of individual peptide ligands to
act across species and clade boundaries gives hope for the identiﬁ-
cation of broad spectrum drugs that act on the same receptor tar-
gets in multiple parasite species. Feeding conﬁdence further is the
fact that some helminth neuropeptide GPCRs are notably promis-
cuous with respect to activating ligand structure (see Greenwood
et al., 2005; McVeigh et al., 2006). Indeed, some neuropeptides
have been shown to display inter-phyla activities in arthropods,
nematodes and platyhelminths (Marks et al., 1997; Mousley
et al., 2004, 2005a,b), highlighting the possibility that drugs acting
at associated receptors could have endectocide potential. Thirdly,
there is much evidence that the neuropeptide complements of
both nematode and platyhelminth parasites are unique and quite
distinct to those seen in vertebrate/host species (see McVeigh
et al., 2005a,b, 2008, 2009). Again, such differences serve to reduce
concerns that toxicity would be an issue for target selective drugs.
Finally, data on functional importance are needed to underpin
the initial selection of targets for progression to focussed, target
validation experiments. With respect to our example selection of
neuropeptide GPCRs, there are much data showing the impact of
neuropeptides (in particular those from the FMRFamide-like pep-
tide [FLP] family) on parasitic helminth tissues with evidence of
physiological effects through peptide application to muscle
strips/muscle ﬁbres/nerves (Day et al., 1994; Cowden and Stretton,
1995; Maule et al., 1995; Pang et al., 1995; Marks et al., 1996;
Fellowes et al., 1998; Davis and Stretton, 2001), and behavioural
modulation through peptide injection (Reinitz et al., 2000) and
RNAi (Kimber et al., 2007; Dalzell et al., 2010). The marked potency
and longevity of neuropeptide actions described in these studies
adds to the appeal of their receptors as targets in that less drug
may be needed to trigger activity and impact worm behaviour.
These data broadly support the potential of neuropeptide GPCRs
as drug targets.
So within the context of our criteria for drug target candidate
selection, targets from within neuropeptide signalling present a
prima facie case for selection. This case appears to be particularly
strong for neuropeptide-activated GPCRs. However, we still await
direct validation that individual neuropeptide GPCRs represent
good anthelmintic targets, especially important in light of potential
concerns about their utility for this purpose. Amongst concerns
raised about their validity as targets is the fact that in human med-
icine, most drugs acting at GPCRs serve to alter the physiological
state of cells or tissues, resulting in modulatory impacts rather
than dramatic alterations that could equate to spastic or ﬂaccid
paralysis/death, desirable endpoints for anthelmintics (one obvi-
ous exception is atropine, a muscarinic AChR antagonist, which
can be lethal to mammals). Further, many of the neuropeptide
families are diverse with numerous structurally similar peptides
(this is especially evident in nematodes), leading to the charge of
inherent functional redundancy. Although this is supported by evi-
dence that some neuropeptide mutant C. elegans present with nor-
mal or wild-type phenotypes (Li et al., 1999), increasing the
diversity of phenotype scoring methods and monitoring the conse-
quences of both knockout and overexpression, are exposing ever-
more functionalities and reducing this concern (Li and Kim, 2008).
Knowing that over-expression (rather than knock-out or knock-
down) is required to reveal phenotypic aberration for a particular
GPCR would demand that screens were tailored to identify agonists
rather than antagonists (see Geary, 2010). Conveniently, in such
circumstances a primary weakness of RNAi-based screens can
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equating to an antagonistic impact on phenotype. Therefore, in a
target validation paradigm, RNAi will select for candidate drug tar-
gets which disrupt worm biology upon knockdown, making them
suitable for antagonistic drug screens.
Whilst there are data supporting the selection of candidate
anthelmintic targets from neuropeptide signalling systems, these
are relatively fragmented and need more data from basic research
if we are to better resolve target selection issues. In an effort to
facilitate progress in this area, the remainder of this review dis-
cusses the merits for what we consider the most obvious anthel-
mintic target candidates associated with neuropeptide signalling.4. Putative anthelmintic targets within the helminth
neuropeptidergic system
Neuropeptidergic signalling pathways can be considered in
terms of three primary divisions, which are discussed separately
below: (1) neuropeptide biosynthesis and synaptic release, (2)
receptors and signal transduction, (3) signal termination.
4.1. Neuropeptide biosynthesis and synaptic release
Both ﬂatworms and nematodes display an ever-growing diver-
sity of peptidergic messengers, encoded by several distinct gene
families, with different naming systems employed between phyla.
Nematodes are currently understood to possess the larger comple-
ment of peptides (the free-living model nematode C. elegans pos-
sesses P250 neuropeptides, with parasitic nematodes likely
displaying similar diversity; McVeigh et al., 2005a, 2006, 2008,
2009; Abad et al., 2008; Kikuchi et al., 2011). Nematode neuropep-
tide genes span three gene families: ﬂp (FMRF-amide-like peptides),
ins (insulin peptide-like), and nlp (neuropeptide-like protein) (see
Marks and Maule, 2010; Li and Kim, 2010, for recent reviews). The
diversity of ﬂatworm neuropeptides has only recently been fully
appreciated,with bioinformatic and proteomic descriptions ofmore
than 100 individual peptides from 10 species (McVeigh et al., 2009;
Collins et al., 2010). While increasing knowledge of these amidated
bioactive peptides has illustrated thewidespread nature and poten-
tial functional diversity of helminth neuropeptide signalling, the
peptides are not viable drugs because of their poor in vivo instability
and poor penetrance of lipid bilayers (Ho et al., 1990; Sheehy et al.,
2000). Attention has instead been directed towards screening for
non-peptide ligands for helminth neuropeptide receptors, although
no such lead compounds have yet been described. Fortunately,
neuropeptide-encoding genes are translated and processed by a
conserved biosynthetic pathway with homologous proteins recog-
nisable in both helminth phyla. If structurally or pharmacologically
distinct from host homologues, these proteins associated with
neuropeptide maturation and signal termination may represent
valuable anthelmintic targets. However, our ability to target these
components is only as good as our knowledge of basic parasite biol-
ogy, and a recurring theme illustrated below is that while C. elegans
and some other models have provided much useful knowledge, our
current understanding of the speciﬁc effectors of neuropeptide sig-
nalling in parasitic helminths is extremely limited. Graphical depic-
tions of neuropeptide processing and signalling pathwayshave been
presented elsewhere (see McVeigh et al., 2005b, 2006; Husson and
Schoofs, 2007a,b; Li and Kim, 2008; Geary, 2010), and are not repro-
duced here.
4.1.1. Transcription and translation of helminth neuropeptide genes
Neuropeptide genes are initially transcribed under the control
of cell-speciﬁc promoters within neuronal nuclei, yielding complex
gene-speciﬁc expression patterns which presumably indicatedifferential functionality. For example, localisation studies in both
nematodes and ﬂatworms reveal complex, distinct and sometimes
overlapping neuropeptide expression patterns (Yew et al., 2005; Li
and Kim, 2008, 2010; Collins et al., 2010; Jarecki et al., 2010; Nanda
and Stretton, 2010). Unsurprisingly, neuropeptide genes are addi-
tionally subject to developmentally- or environmentally-regulated
expression by micro-RNA (miRNA)-based post-transcriptional reg-
ulation (several ﬂp-miRNAs have been described in the plant para-
sitic nematode Bursaphelenchus xylophilus (Huang et al., 2010)).
Such mechanisms raise the (currently) remote possibility of
anthelmintic therapy based on inhibition of miRNAs – an approach
proposed as a possible future anti-cancer therapy (reviewed by
Nana-Sinkam and Croce (2010, 2011)), although the applicability
of these approaches to helminths remains untested.
Following nuclear export and splicing, neuropeptide mRNAs are
translated directly into a precursor protein (also referred to as a
prepropeptide), which may incorporate single or multiple copies
of mature neuropeptides. The precursor is, during translation,
translocated into the endoplasmic reticulum (ER) lumen and thus
into the classical regulated secretory pathway, which involves
transit through the trans-Golgi network, packaging and concentra-
tion into large dense-cored secretory vesicles (LDCVs), axonal
transport, and eventual release at the synapse (Emanuelsson
et al., 2007; Zhang et al., 2010). Recognition of the prepropeptide’s
nascent N-terminal secretory signal peptide is thought to occur
upon its translational emergence from the ribosome, by a signal
recognition particle (SRP), which binds the signal peptide and
transports the entire ribonucleoprotein complex to an ER channel
known as a translocon, through which the growing prepropeptide
is inserted into the ER lumen. Reverse genetics experiments on a C.
elegans SRP homologue (Table 1) reveal a range of aberrant motility
and developmental phenotypes consistent with SRP’s role at the
apex of the classical secretory pathway. Although this protein rep-
resents an appealing target, it is difﬁcult to envisage a mechanism
which could therapeutically and speciﬁcally inhibit this molecule’s
function, short of targeting the protein–protein interaction (a
wider strategy proposed by Taylor et al. (2011)) between SRP
and prepropeptide. This process of classical secretion/exocytosis
is thought to exist in all of the eukarya (Blobel and Dobberstein,
1975; Koch et al., 2003). Within the ER lumen, the signal peptide
is ﬁrst cleaved from the precursor by a membrane-bound signal
peptidase complex. Molecular disruption of a C. elegans signal pep-
tidase gene (phi-20; Table 1) demonstrates a range of aberrant phe-
notypes including paralysis. Similarly, when a subunit of the plant
parasitic nematode Meloidogyne incognita signal peptidase (MiS-
PC3) was targeted by RNAi, a 50% reduction in the number of
M. incognita recovered from plant roots was reported (Charlton
et al., 2010).
4.1.2. Prepropeptide processing
Once bereft of signal sequence, the peptide precursor is next
cleaved by prohormone/proprotein convertase (PC) enzymes (also
known as neuroendocrine convertases) situated within LDCVs.
These enzymes belong to the subtilisin/kexin-like superfamily of
serine proteases which are responsible for post-translational pro-
cessing of a range of secretory proteins in both prokarya and euk-
arya. Prohormone convertase PC2 and PC1/3 families are involved
in processing within the regulated secretory pathway of inverte-
brate neuronal and endocrine tissues (Seidah, 2011), and indeed
available evidence suggests that PC2 orthologues play a conserved
role in helminth neuropeptide processing (Reddien et al., 2005;
Husson et al., 2006). Functionally, PC2 excises peptides from their
prepropeptide by C-terminal cleavage of basic amino acid motifs
which ﬂank mature peptides in prepropeptides. Basic motifs most
commonly consist of pairs of the basic amino acids lysine and/or
arginine (although some variation on this pattern has been noted
Table 1
Neuropeptide pathway genes that following knockout or RNA interference induce deleterious phenotype in Caenorhabditis elegans. Note that some of these genes do not function
exclusively within neuropeptide signalling pathways, and are involved more generally in cellular secretory processes.
Protein C. elegans D. melanogaster Helminths
Neuropeptide biosynthesis
Signal recognition
particle
F08D12.1, larval arrest/late larval arrest,
locomotion variant, embryonic lethal. larval
lethal1,2,3,4,5,6
Srp72, no phenotype available Schmidtea mediterranea: blastema
abnormal; body lesions; lysis;
photoreceptors abnormal7
Signal peptidase
complex
phi-20, Paralysed, larval lethal, embryonic
lethal, maternal sterile2,4,5,8,9,10,11,12
Spase22-23, no phenotype data available Meloidogyne incognita: reduced
infectivity of plant roots13
Prohormone
convertase PC2
egl-3, Egg retention, egg-laying defective,
coiler14
Amon, developmental defects, larval arrest,
defective larval motility15
S. mediterranea: aberrant motility
(paralysis, abnormal ﬂipping, abnormal
responses to touch, vibration and
light)7
PC2 chaparone, 7B2 Sbt-1; no deleterious phenotypes reported 7B2; no phenotype data available. S. mediterranea: blastema abnormal;
behaviour abnormal (sluggish,
abnormal ﬂipping, abnormal vibration
response, light response abnormal);
ﬂattened posture7
Carboxypeptidase E egl-21, Egg retention, egg-laying defective,
coiler14
No direct orthologue16
Peptidylglycine-a-
amidating
monooxygenase
T19B4.1, sterile, lethal [WB]
Large dense core
vesicle kinesin,
unc-104/klp-1, Sterile, locomotion variant,
lethal5 [WB]
Unc-104, aberrant larval motility17
Calcium-activated
protein for secretion
(CAPS)
unc-31/egl-22, Egg-laying defective, paralysed,
ﬂaccid, locomotion variant, egg-retention,
sluggish14,18
CAPS; embryonic/larval lethal19
Syntaxin syn-1/syx-3, Sterile, lethal [WB]; Syn-4/syx-4,
embryonic lethal, maternal sterile, reduced
brood size9,20; unc-64, locomotion variant21
Syx1A, temperature-dependent paralysis,
multiple developmental defects, larval
paralysis and lethality22
Tomosyn tom-1, Locomotion variant, larval lethal,
embryonic lethal2,10,23
Tomosyn, no deleterious phenotypes reported
Neuropeptide signal transduction
Insulin receptors daf-2, Sterile, locomotion variant, larval lethal,
reduced brood size, lethal24
G-protein a subunits gsa-1, egl-30, goa-1, Egg laying defective,
locomotion variant, sterile progeny, maternal
sterile, larval lethal, reduced life-span,
sluggish2,6,20,23; gpa-12, egg laying variant,
embryonic lethal, locomotion variant25
G-salpha60A, larval lethal26
G-protein b and c
subunits
gpb-1, Locomotion variant, larval lethal, egg
laying variant, embryonic lethal, maternal
sterile2,5; gpb-2, coiler27; gpc-2, sterile,
embryonic lethal, sick, lethal28
Gbeta13F, developmental defects29
Regulators of G-protein
signalling (RGS)
proteins
eat-16, Hyperactive egg laying, sterile, body
bend variant, hyperactive, early eggs laid,
lethal30; rgs-9, embryonic lethal31; rgs-10,
embryonic lethal, maternal sterile32
CG42450, no phenotype available S. mediterranea: blastema abnormal;
photoreceptors abnormal; light
response abnormal; variably abnormal
[7]
Adenylate cyclase acy-2, locomotion variant2; acy-4, sterile, male
mating defective, lethal [WB]
AC13E, AC76E, AC3, CG43373, Ac78C no
phenotypic data available; Rut, no deleterious
phenotypes reported
Protein kinase A kin-1, egg-laying variant, larval lethal9 Pka-C1, embryonic lethality, slow
development33; CG32944, no phenotype data
available
Phospholipase C-b egl-8, Sterile, male sterile, egg-laying defective,
egg-laying variant, posterior body wall
contraction defective28,34
norpA, no deleterious phenotypes reported
IP3 channel itr-1, Sterile, maternal sterile, lethal2,5 [WB] Itp-r83A, no deleterious phenotypes reported
Synaptic peptidases
Neprilysin nep-1, Maternal sterile31; C49D10.10,
embryonic lethal2
Nep2, no phenotype data available. CG15485,
no phenotype data available
Deleterious refers to lethality, reduced lifespan, or aberrant motility or reproduction. Phenotype data from WormBase (http://www.wormbase.org; WS225 16/06/2011),
FlyBase (http://www.ﬂybase.org; FB2011_07, 21/07/2011) or as referenced: 1Gaiser et al. (2009), 2Simmer et al. (2003), 3Hamamichi et al. (2008), 4Sonnichsen et al. (2005),
5Kamath et al. (2003), 6Sieburth et al. (2005), 7Reddien et al. (2005), 8Gonczy et al. (2000), 9Rual et al. (2004), 10Balklava et al. (2007), 11Nollen et al. (2004), 12Frand et al.
(2005), 13Charlton et al. (2010), 14Trent et al. (1983), 15Rayburn et al. (2003), 16Settle et al. (1995), 17Barkus et al. (2008), 18Speese et al. (2007), 19Renden et al. (2001), 20Ceron
et al. (2007), 21Brenner, 1974, 22Littleton et al. (1998), 23Fraser et al. (2000), 24Malone and Thomas, 2004, 25Yau et al. (2003), 26Wolfgang et al. (2001), 27Avery, 1993, 28Lehner
et al. (2006), 29Schaefer et al. (2001), 30Porter and Koelle, 2010, 31Maeda et al. (2001), 32Fernandez et al. (2005), 33Perrimon et al. (1996), 34Espelt et al. (2005).
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2005a; Rehfeld et al., 2008). PC2 orthologues have been character-
ised in C. elegans (egl-3, named for its identiﬁcation from a screen
for egg-laying mutants), and Schmidtea mediterranea. In both of
these species, reverse genetics analyses (Table 1) have validateddisruption of PC2 as having deleterious effects on helminth biol-
ogy, including effects on motility, behaviour and reproduction
(Trent et al., 1983; Kass et al., 2001; Reddien et al., 2005). While
such effects are not lethal in these free-living species, therapeutic
effects of a similar magnitude in a parasite, resident in a more
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ity for the parasite. In C. elegans this disruption almost completely
ablates the normal proﬁle of FLP neuropeptides seen in N2 (wild-
type) worms (Husson et al., 2006), perhaps explaining the global
effects described above. Disruption of PC2’s chaperone protein
‘7B2’ (a protein required for the normal transport, activation and
regulation of PC2 (Van Horssen et al., 1995; Muller et al., 1997;
Lee and Lindberg, 2008)) has similarly severe effects on the C. ele-
gans FLP proﬁle (Husson et al., 2007). Speciﬁc small-molecule
inhibitors have been reported as active against murine PC2, dem-
onstrating >90% inhibition with Ki values in the sub-lM range
(Kowalska et al., 2009), indicating the possibility of developing
similar lead compounds with therapeutic activity against helminth
PC2. Although no pharmacological or structural studies have been
performed on helminth PC2 enzymes, it is perhaps worth noting
that nematode PC2/EGL-3 orthologues exhibit a unique sequence
insert within the catalytic domain, which may indicate the possi-
bility of nematode-speciﬁc pharmacology (Kovaleva et al., 2002),
potentially permissive of pharmacological differentiation between
host and helminth enzymes. A Schistosoma mansoni PC2 orthologue
was suggested as a drug target candidate in a chemogenomics
screen based on proteins displaying deleterious mutant pheno-
types in both C. elegans and Drosophila melanogaster (Caffrey
et al., 2009), although this was not supported by RNAi studies from
the same laboratory (Stefanic´ et al., 2010), which described the ab-
sence of aberrant phenotypes associated with RNAi of 11 schisto-
some targets.
Since PC2 cleaves C-terminally to dibasic markers, its cleavage
results in excision of a glycine-extended peptide intermediate
which retains a C-terminal dibasic motif. Before further processing
can occur, this extension must be removed by carboxypeptidase E
(CPE) activity, as demonstrated by proteomics analysis of C. elegans
mutants deﬁcient in the CPE orthologue, egl-21, which displayed a
peptide proﬁle consisting almost exclusively of unprocessed, C-ter-
minally extended peptides (Husson et al., 2007), allied to a range of
aberrant phenotypes (Table 1). Although small molecule inhibitors
have been described for other metallocarboxypeptidases (Fernán-
dez et al., 2010), none have yet been discovered with speciﬁc activ-
ity against CPE.
4.1.3. Neuropeptide amidation
Most helminth neuropeptides are C-terminally amidated,
where the sequential actions of PC2 and CPE liberate a C-terminal
glycine-extended prepeptide which is then subject to amidation
(enzymatic production of a C-terminal NH2 moiety), a process that
represents the ﬁnal step in neuropeptide maturation. Amidation is
a two-step process in which two enzymes act sequentially: (1)
peptidyl a-hydroxylating monooxygenase (PHM), a copper-, oxy-
gen- and ascorbate-dependent enzyme, ﬁrst catalyses hydroxyl-
ation of the pre-peptide C-terminal glycine, to yield an alpha-
hydroxyglycine-extended peptide (Eipper et al., 1992; Kulathila
et al., 1999), (2) peptidyl-alpha-hydroxyglycine alpha-amidating
lyase (PAL), a zinc dependant enzyme, catalyses the secondary
dealkylation of the alcohol amide intermediate to form the al-
pha-amidated neuropeptide and a glyoxylate by-product (Eipper
et al., 1992; Kulathila et al., 1999).
In vertebrates, PHM and PAL exist as a bifunctional protein des-
ignated peptidylglycine alpha-amidating monooxygenase (PAM;
for review see Prigge et al., 2000). Several invertebrate species,
including the ﬂatworms Dugesia japonica (Asada et al., 2005), and
S. mansoni (Mair et al., 2004; Atkinson et al., 2010), encode mono-
functional PHM and PAL enzymes on distinct genes, while nema-
todes including C. elegans, encode multiple copies of bi- and
monofunctional enzymes. The biological signiﬁcance of such ge-
netic complexity remains unclear. Amidating enzymes similarly
have widespread expression within helminth nervous systems(Mair et al., 2004; Atkinson et al., 2010). Using an anti-PHM antise-
rum we have been able to visualise the entire amidated neuropep-
tide system of adult schistosomes (Fig., 1), revealing previously
unrecognised levels of neuronal complexity and supporting
hypotheses on the importance of amidated neuropeptides to schis-
tosome biology. This importance is directly illustrated by the re-
duced activity of glycine-extended free-acids (<10%) in
comparison to their alpha-amidated counterparts (Eipper et al.,
1992; Bowman et al., 1996; Bolkenius and Ganzhorn, 1998; Kulat-
hila et al., 1999; Prigge et al., 2000; Bowman et al., 2002; McVeigh
et al., 2011). Further, C-terminal amidation was shown to be criti-
cal to the activity of a myoexcitatory peptide on dispersed schisto-
some muscle ﬁbres (Day et al., 1997), supporting the importance of
the C-terminal amide signature for myoactivity in schistosomes.
Importantly, no alternative mechanism for the in vivo amidation
of neuropeptides has been documented.
Commercially available inhibitors of PHM/PAL/PAM act by inhi-
bition of conserved active site mechanisms, and would therefore
likely be toxic to both parasite and host enzymes. Thus, the identi-
ﬁcation of differences between host and helminth enzymes is key
to unearthing their potential as novel parasite drug targets. Func-
tional data from characterised helminth enzymes such as schisto-
some PHM and PAL (Mair et al., 2004; Atkinson et al., 2010)
indicate that while structural similarities remain evident within
conserved active site motifs, marked catalytic and in some
cases subtle structural differences between vertebrate and parasite
enzymes may provide for successful chemotherapeutic
discrimination.
On the face of it, peptide amidation, a process mandatory for the
biological activity of most neuropeptides, is an appealing compo-
nent of the neuropeptide signalling system for anti-parasitic inter-
vention. As such, much of the appeal of targeting either enzyme is
the likelihood that their dysfunction would compromise all forms
of amidated neuropeptide signalling and, thereby, disrupt all the
associated parasite processes and behaviours. One would hypothe-
sise that this would be catastrophic to worm biology and survival.
Clearly, using reverse genetic tools to probe this hypothesis is an
important step in the drug target validation process. Whilst this
has been attempted in S. mansoni, knockdown for Sm-phm-1 and
Sm-pal-1 was inconsistent preventing valid phenotypic assess-
ments (Atkinson et al., 2010). To date most of the phenotypic evi-
dence from RNAi based attempts to disrupt the helminth
neuropeptide amidation process comes from large scale RNAi
experiments in C. elegans, which have reported sterile, lethal and
aldicarb resistant phenotypes (see Table 1); Drosophila phm loss-
of-function mutants display lethal phenotypes (Jiang et al., 2000).
Clearly, the validation of amidating enzymes as targets would be
strongly supported by RNAi-based evidence of profound pheno-
typic aberration in parasites. In the absence of these data the po-
tential of PHM and PAL as anthelmintic targets remains to be
established.
4.1.4. Docking and release of synaptic large dense-cored vesicles
Upon arrival in the synaptic terminal, neuropeptide-containing
LDCVs are ready for release into the synapse. Available evidence
from C. elegans suggests that in nematodes, these processes employ
similar molecular mechanisms to those of higher organisms (in-
deed, all of the proteins mentioned below have clear orthologues
in all of the major model organisms, including humans) although
there is currently insufﬁcient evidence to enable rational identiﬁ-
cation of prospects for chemical intercession within this system.
Current understanding of the C. elegans LDCV release mechanism
is limited, but implicates an UNC-104 kinesin in LDCV antero-grade
axonal transport (Zahn et al., 2004) (UNC-116 may also be in-
volved; Li and Kim, 2008). Only three proteins have been identiﬁed
as speciﬁcally required for aspects of LDCV docking, priming and
Fig. 1. The amidated neuropeptide system of an adult female Schistosoma mansoni. Peptidyl a-hydroxylating monooxygenase (PHM)-immunoreactivity (IR) appears green
(ﬂuorescein isothiocyanate [FITC]-labelled secondary antibody) whilst ﬁlamentous actin in muscle ﬁbres appears red (tetramethyl rhodamine isothiocyanate [TRITC]-labelled
phalloidin). (A) Extensive PHM-IR in the paired cerebral ganglia (⁄), main nerve cords (MNC) and nerve processes innervating the oral sucker (Os), oesophagus (Oes),
acetabulum (Ac), uterus (U) and gut (Gt) in the anterior region of a female schistosome. The outer surface of the fore body region is covered in immuno positive sensory
endings (arrow heads). (B) PHM-IR just posterior to the oral sucker (Os) in one of the main nerve cords (MNC) and associated nerve net that provides branches to the
numerous sensory endings (arrow heads) of the anterior-lateral forebody. Note that the tegument is not visible; body wall muscle (M). Scale bars: A = 30 lm; B = 12 lm.
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ing protein (Speese et al., 2007; Hammarlund et al., 2008; Lin
et al., 2010); syntaxin, a component of the SNARE (soluble N-
ethyl-maleimide-sensitive fusion protein attachment receptor)
complex involved in LDCV-membrane fusion (Hammarlund et al.,
2008); and tomosyn, an inhibitor of LDCV exocytosis (Gracheva
et al., 2007a,b). Other membrane proteins implicated in exocytosis
of synaptic vesicles (carrying classical neurotransmitters;
Richmond, 2007) may also have roles in LDCV exocytosis.4.2. Neuropeptide receptors and signal transduction mechanisms
4.2.1. Insulin-like receptor tyrosine kinases
While the vast majority of neuropeptides in helminths, and
throughout nature, are thought to exert their effects via GPCRs,
insulin-like peptides signal through conserved receptor tyrosine
kinase (RTK)-based mechanisms, which represent proven drug tar-
gets for an existing arsenal of anti-phosphorylation drugs used in
cancer chemotherapy (Levitzki and Gazit, 1995). Although only a
single homologue of mammalian insulin receptors has been de-
scribed in C. elegans (Kimura et al., 1997), this species appears to
possess an additional suite of structurally-divergent insulin-like
receptors (Dlakic, 2002). Currently, no insulin receptors have been
characterised from parasitic nematodes, although seven insulin-
like peptide-encoding gene orthologues were recently identiﬁed
in the genome of the plant parasitic nematode, B. xylophilus (Kiku-
chi et al., 2011). In contrast, insulin receptors have been identiﬁed
from parasitic platyhelminths with some success – an insulin-like
RTK (EmIR) has been identiﬁed in the cestode Echinococcus
multilocularis (Konrad et al., 2003). Unfortunately, similar insulin-binding kinetics of the cestode and human insulin receptors could
raise concerns about the potential toxicity of therapeutic agents
active at the cestode receptor. Two insulin receptors have been de-
scribed in S. mansoni (SmIR-1, -2) and Schistosoma japonicum (SjIR-
1, -2) (Vicogne and Dissous, 2003; Khayath et al., 2007; Ahier et al.,
2008; You et al., 2010, 2011), both of which possess sequence in-
serts within tyrosine kinase domains that are absent from the hu-
man insulin receptor. You et al. (2010) demonstrated that these
inserts do not affect the functionality of the TK fold, but are pre-
dicted to be highly antigenic and are proposed as potential struc-
tural targets for the design of anti-SmIR vaccines or inhibitors.4.2.2. Neuropeptide-like G protein-coupled receptors
The vast majority of neuropeptide effects are mediated by
GPCRs, which, upon ligand binding, recruit a heterotrimeric GTP-
binding protein (aka G-protein) through which intracellular signal
transduction is mediated. Neuropeptide-activated GPCRs have
drawn much attention from industrial and academic drug discov-
ery research groups thanks largely to the proven druggability of
this receptor family, and perhaps by the novel anthelmintic emo-
depside, one target of which appears to be nematode latrophil-
lin-like GPCRs (Saeger et al., 2001; Welz et al., 2005; Krüger
et al., 2009; Mühlfeld et al., 2009). From an industrial point of view
the appeal of GPCR targets is further enhanced by an array of exist-
ing heterologous expression and assay technologies (Greenwood
et al., 2005; Minic et al., 2005; Woods et al., 2010). GPCRs are
implicated as mediators of neuropeptide signalling events in both
helminth phyla, and escape major concerns associated with
anthelmintic ﬁeld-resistance. The value of neuropeptide GPCR drug
targets has been recognised by the Bill andMelinda Gates Foundation
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(McGill University) in collaboration with two African universities,
aiming to identify FLP GPCR ligands from natural product
extracts (http://www.gatesfoundation.org/Grants-2008/Pages/
McGill-University-OPP52088.aspx).
Despite the undeniable potential of helminth GPCRs as targets
for novel anthelmintics, our understanding of their basic biology
is limited and fragmentary, such that we can point to speciﬁc func-
tions of only a handful of helminth peptide GPCRs, all from C. ele-
gans – at the time of writing, not one peptide GPCR has been
functionally characterised from a parasitic worm. Functional data
from model helminths have centred on receptor deorphanisation
(ligand-receptor matching) and/or reverse genetics analyses, as de-
scribed below.4.2.2.1. Peptide GPCRs in Nematoda. Estimates of the extent of the C.
elegans peptide-GPCR complement vary widely between published
studies (Bargmann, 1998; Keating et al., 2003; Fredriksson and
Schiöth, 2005), with the most recent analysis suggesting that C. ele-
gans possesses as many as 91 peptide receptor genes encoding 125
distinct GPCRs (Janssen et al., 2010); similar ﬁgures are not yet
available for any parasitic nematode. C. elegans therefore repre-
sents the source of much of our current understanding of helminth
GPCR function, having supported studies into both receptor deo-
rphanisation and functional characterisation. Functional genomics
studies in C. elegans have exposed some peptide GPCRs that associ-
ate with deleterious phenotypes such as lethality, reduced lifespan,
compromised motility or aberrant reproductive function; a subset
of these have been deorphanised (Table 2). Assuming functional
conservation, parasite orthologues of these receptors would have
obvious appeal as candidate chemotherapeutic targets. The C. ele-
gans database (WormBase) identiﬁes 21 putative peptide GPCRs
that yield deleterious phenotypes following knockout or RNAi
analysis (Table 2), effectively simulating antagonistic pharmacol-
ogy at these receptors. Perhaps most promising, are ﬁve GPCRs
for which reduced function leads to lethality and/or sterility,
including one of the FLP-18 receptors (Y58G8A.4/FLP18R2). Six
GPCRs yield phenotypes associated primarily with altered motility,Table 2
Neuropeptide-like G protein-coupled receptors (GPCRs) that following knockout or RNA in
GPCR Most potent ligand Aberrant phe
Y58G8A.4 (FLP18R2) FLP-181 Sterile, letha
C54A12.2 Embryonic le
AC7.1/TAG-49 Embryonic le
T23B3.4 (CKR-1) Embryonic le
C30F12.6 (NMUR-4) Larval arrest
C10C6.2 (NPR-3/FLP-15R) FLP-158 Some paraly
F59D12.1 Paralysed, lo
Y54E2A.1 Locomotion
T05A1.1 (NPR-2) Locomotion
T02E9.1 Locomotion
C04E6.9 (SRD-16) Locomotion
C16D6.2 (FLP18R1) Reduced fert
Y59H11AL.1 (VRFaR2) FLP-711 Reduced bro
T22D1.12 (NPR-12) Reduced bro
F41E7.3 Fewer egg-la
C25G6.5 (NPR-11/FLP-21R) FLP-2112 Fewer egg la
F21C10.12 Egg laying d
F54D7.3 (GnRHR) NLP-4714 Delayed egg
Y39A3B.5 (CKR-2) NLP-1215 Reduced life
T27D1.3 (NPR-15) Organism de
C26F1.6 (VRFaR1) FLP-717 Hyperactive
F35G8.1 Hyperactive
Deleterious refers to lethality, reduced lifespan, or aberrant motility or reproduction. W
orthologues in D. melanogaster, but (with the exception of F54D7.3) all are listed on Fly
2011). Phenotype data from WormBase (http://www.wormbase.org; WS225 16/06/2011
(2003), 4Simmer et al. (2003), 5Rual et al. (2004), 6Park et al. (2010), 7Ceron et al. (2007)
(2006), 12Lowery et al. (2003), 13Gort et al. (2008), 14Lindemans et al. (2009), 15Janssenincluding the FLP-15 receptor NPR-3 (C10C6.2), which yields re-
duced egg output, alongside aberrant locomotion and paralysis in
some animals (see Keating et al., 2003). Ablation of nine more
receptors triggers reduced/compromised reproductive capacity.
These lethal, motility and reproductive phenotypes are consistent
with deleterious anthelmintic treatment outcomes, and go some
way towards validating the utility of antagonistic chemotherapy
at neuropeptide GPCRs. The potential for agonist activity at nema-
tode neuropeptide receptors has been demonstrated by a large
body of literature describing the effects of FLPs on Ascaris suum
neuromuscular bioassays, in which FLPs have been shown to have
potent effects on somatic, pharyngeal and ovijector muscle prepa-
rations (Maule et al., 1995; Holden-Dye et al., 1997; Fellowes et al.,
1998; Marks et al., 1999; Reinitz et al., 2000; Davis and Stretton,
2001; Purcell et al., 2002a,b; Moffett et al., 2003; Mousley et al.,
2004; Papaioannou et al., 2005). Promising as these potential tar-
gets are, their further validation is hindered by our ignorance of
parasite orthologues. Identiﬁcation and characterisation of such
orthologues should be a priority for GPCR-directed anthelmintic
discovery programmes. Although there are many other C. elegans
peptide GPCRs that correlate with more subtle functions and so
lack obvious appeal as anthelmintic targets, their homologues
may prove valuable as targets in parasites. More general discus-
sions of the biology of C. elegans peptide GPCRs are available else-
where (Li and Kim, 2008, 2010; Mousley et al., 2010).4.2.2.2. Peptide GPCRs in Platyhelminthes. In ﬂatworms, knowledge
of peptide GPCRs has recently been accelerated by analysis of the
trematode S. mansoni (Berriman et al., 2009) and planarian S. med-
iterranea (Robb et al., 2008) genomes, from which respectively at
least 35 and 81 putative peptide receptors (Rhodopsin-like family
GPCRs) have been described (Fitzpatrick et al., 2009; Zamanian
et al., in press), as well as a divergent, ﬂatworm-speciﬁc clade of
19 S. mansoni and 40 S. mediterranea GPCRs, known as PROF1
(Platyhelminth-speciﬁc, Rhodopsin-like, Orphan Family (1) recep-
tors (Zamanian et al., in press). Although these display no homol-
ogy to any other GPCRs that could inform ligand class/structure,
some of them could conceivably be neuropeptide-activated. Giventerference induce deleterious phenotype in Caenorhabditis elegans.
notypes reported
l
thal2
thal, sick, maternal sterile3,4
thal, reduced life span, reduced brood size5,6
, sterile, embryonic lethal7
sis, locomotion variant, reduced brood size, sluggish9
comotion variant, sluggish, ﬂat locomotion path, frequency body bend reduced9
variant, maternal sterile5,6
variant, locomotion reduced, kinker9
variant, sluggish, body bend reduced9
variant10
ility, fewer egg-laying events during active9
od size7
od size5
ying events during active9
ying events during active
efective13
laying14
span6
velopment variant16
egg laying9
egg laying9
here known, most potent ligand is indicated. Note that most of these GPCRs have
Base as ‘no phenotypic data available’ (http://www.ﬂybase.org; FB2011_07, 21/07/
), or as referenced: 1Kubiak et al. (2008), 2Sonnichsen et al. (2005), 3Kamath et al.
, 8Kubiak et al. (2003), 9Keating et al. (2003), 10Zugasti et al. (2005), 11Mertens et al.
et al. (2008), 16Byrne et al. (2007), 17Mertens et al. (2004).
P. McVeigh et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 76–91 85their unique existence in phylum Platyhelminthes, PROF1 GPCRs
represent candidate drug targets with potentially unique pharma-
cology, which could promote exquisite drug selectivity between
host and parasite GPCRs. An additional FLP-activated GPCR (Gt-
NPR-1) has been described in the planarian ﬂatworm, Girardia tigri-
na (Omar et al., 2007). Gt-NPR-1, heterologously expressed in Chi-
nese hamster ovary cells, was activated by FLPs emanating from
both ﬂatworms and nematodes and as such, currently represents
the sole deorphanised neuropeptide receptor from any ﬂatworm.
Notably, the existence of clear Gt-NPR-1 orthologues in both S.
mansoni and S. mediterranea (Zamanian et al., in press), provides ta-
cit support for employing planarian model systems for the study of
parasitic ﬂatworm receptors. This is an important observation, gi-
ven that presently no ﬂatworm peptide GPCR has been subject to
direct functional characterisation, making it impossible to directly
validate any individual ﬂatworm receptor as an anthelmintic target
– planarians represent useful tools in the push towards functional
characterisation of conserved GPCRs in phylum Platyhelminthes.
4.2.3. Peptide-gated ion channels
GPCRs represent the prevalent mechanism of neuropeptide sig-
nal reception and transduction, eliciting the long-term, metabotro-
pic, modulatory effects that are characteristic of neuropeptides.
However, neuropeptide-gated ion channels have also been re-
ported as mediators of fast synaptic transmission in molluscan
(Cottrell et al., 1990; Lingueglia et al., 1995; Jeziorsky et al.,
2000; Furukawa et al., 2006) and cnidarian (Golubovic et al.,
2007) nervous systems. Intriguingly, similar channels may also ex-
ist in parasitic nematodes. One nematode FLP (PF4 - Panagrellus
redivivus FLP #4; KPNFIRFamide; Maule et al., 1995), displays a un-
ique activity proﬁle, having been shown in patch-clamp experi-
ments to directly gate a population of low-conductance Cl
channels on A. suum somatic muscle, leading to a fast hyperpolar-
isation of Ascaris body wall muscle preparations in vitro, with con-
sequent muscular ﬂaccid paralysis (Maule et al., 1995; Holden-Dye
et al., 1997; Purcell et al., 2002a,b). This implies the existence in
parasitic nematodes of a muscle-expressed peptide-gated Cl
channel (here referred to as a ‘PF4 receptor’). Such receptor chan-
nels are not known to exist in mammalian hosts, and therefore rep-
resent a target of potentially unique, and consequently selective,
pharmacology, against which agonists or antagonists could elicit
deleterious effects on parasite neuromuscular function. Other hel-
minth ligand-gated ion channels are of proven druggability since
they already represent targets for the majority of current front-line
anthelmintics – levamisole, morantel, pyrantel, paraherquamides
and the AADs act by modulating the function of nAChRs (Atchison
et al., 1992; Zinser et al., 2002; Kaminsky et al., 2008) while the
macrocyclic lactones act through GABA – and glutamate-gated
Cl channels (Arena et al., 1992; Wolstenholme and Rogers,
2005). It is clear that helminth ligand-gated ion channels have
demonstrable drug-discovery potential and that the PF4 receptor,
as a unique example of that group, warrants further research direc-
ted towards its identiﬁcation and characterisation.
4.2.4. GPCR signal transduction mechanisms
GPCRs signal through a conserved mechanism involving recruit-
ment of a heterotrimeric G-protein complex, an event that is trig-
gered by ligand binding to the GPCR, through which signals are
transduced in order to initiate an intracellular response. Current
understanding of the intimate details of this signalling process
have been reviewed elsewhere (McCudden et al., 2005; Bastiani
and Mendel, 2006), and are considered only brieﬂy here. G-protein
heterotrimers, consisting of a, b and c subunits exist at rest on the
cytosolic face of the membrane, with the alpha subunit bound to
GDP. Interaction of a congruent ligand with a GPCR triggers recruit-
ment of this complex, in concert with activation of the G-protein asindicated by the Ga’s exchange of GDP for GTP. The conventional
view is that upon activation, the Ga subunit dissociates from the
Gbc complex, allowing Ga and Gbc to exert separate and distinct
downstream effects. Ga’s intrinsic GTPase activity tends to catabo-
lise GTP into GDP (a process that is accelerated both by interaction
with effectors and speciﬁc regulatory proteins), returning Ga to its
resting state following effector interaction, at which time it tends
to re-associate with Gbc. Ga-GTP and Gbc can both interact with
several effector proteins, although diversity within Ga subtype
(classiﬁed according to the effector enzymes with which each class
interacts) is the main determining factor in G-protein functional
diversity.
The C. elegans complement of heterotrimeric G-proteins is well
characterised, encompassing 21 Ga, 2 Gb and 2 Gc subunits. The
Ga family includes single orthologues of each of the recognised
mammalian Ga subunits: Gs (gsa-1), Gi/o (goa-1), Gq (egl-30) and
G12 (gpa-12). C. elegans additionally possesses a divergent clade
of 17 genes lacking clear homology to any other Ga class, but most
similar to Gi/o-like genes (Bastiani and Mendel, 2006). Reverse
genetics of the core C. elegans Ga orthologues expose a variety of
aberrant phenotypes beﬁtting of their core role in cell signalling
(Table 1), while the divergent Ga genes described above do not
yet appear to have been subject to detailed functional interroga-
tion. Both of the C. elegans Gb and one of the two Gc subunit genes
display aberrant mutant phenotypes. This suggests that functional
redundancy is largely absent within Gb and Gc genes, and that
these proteins may then represent an appealing metabolic
‘choke-point’ against which therapeutics may be targeted (Smrcka
et al., 2008; Dessal et al., 2008, 2011). At present there are no
descriptions of G-protein sequences from parasitic nematodes.
Knowledge of ﬂatworm G-proteins is similarly sparse, with cloned
sequences available only for S. mansoni Gas, Gai and Gao subunits
(Mansour and Mansour, 1989; Iltzsch et al., 1992). Parasite G-pro-
teins can be targeted therapeutically by suramin, an inhibitor of
Ga-GPCR coupling used in both trypanosomiasis and onchocercia-
sis chemotherapy, and also in human cancer therapy (although
suramin is a notoriously promiscuous drug) (Voogd et al., 1993;
Höller et al., 1999). Further drug targeting of Ga function seems
possible given descriptions of Ga modulators, which have been
proposed as drugs for use in inherited human disorders related
to Ga malfunction (Chahdi et al., 1998; Ja et al., 2006). Aside from
the divergent clade of C. elegans Ga genes described above, no evi-
dence is currently available on the existence of pharmacological or
structural differences between mammalian and helminth G-pro-
tein function, consistent with parasite-speciﬁc drug function. In-
deed, cursory BLAST searches indicate high levels of amino-acid
sequence identity and similarity in comparisons between human
and schistosome Ga subclasses (unpublished data), such that
achieving selective interference with parasitic helminth G-protein
function might be a challenge. There is growing interest in a family
of Ga-regulatory proteins (regulators of G-protein signalling; RGS
proteins) as drug targets in human medicine (McCudden et al.,
2005; Kimple et al., 2007; Sjögren et al., 2010). RGS proteins are
GTPase-accelerating factors that act as desensitisers of G-protein
signalling, and as such represent an attractive additional target
set within GPCR-related signalling pathways. Data on RGS protein
structure and function is completely lacking in parasitic helminths,
although C. elegans RGS homologues have been well characterised
(Table 1) (Chase and Koelle, 2004; Hess et al., 2004; Hiley et al.,
2006; Ferkey et al., 2007; Porter et al., 2010; Esposito et al., 2010).
Physiological investigation of the signal transduction mecha-
nisms employed by helminth neuropeptides have illuminated sev-
eral potential drug targets functioning downstream of peptide
GPCRs. The key postsynaptic intracellular mechanisms implicated
in helminth neuropeptide actions are the adenylate cyclase and
phosphatidylinositol pathways. In the adenylate cyclase pathway,
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cyclic adenosine monophosphate (cAMP) from adenosine triphos-
phate (ATP). cAMP activates protein kinase A (PKA), which can eli-
cit cellular effects by phosphorylation of enzymes, contractile
proteins or ion channels. The ﬁrst step in the phosphatidylinositol
pathway is activation of b-class phospholipase C (PLC) by Gaq,, pro-
cessing phosphatidylinositol (4,5) bisphosphate (PIP2) into the sec-
ond messengers inositol (1,4,5) triphosphate (IP3) and
diacylglycerol (DAG). IP3 liberates intracellularly sequestered Ca2+
from the sarcoplasmic reticulum (SR) by opening of IP3-gated
Ca2+ channels, while DAG simulates protein kinase C (PKC) to
phosphorylate cellular effectors. It is these second messengers that
trigger the ultimate cellular effects reported of helminth neuropep-
tides. Studies in ﬂatworms illustrate a dichotomy between signal-
ling pathways employed by two of the primary classes of ﬂatworm
neuropeptides: ﬂatworm neuropeptide Fs (NPFs) share a conserved
neuropeptide Y (NPY)-like mechanism, signalling through depres-
sion of cellular cAMP levels (presumably by inhibition of adenylate
cyclase activity) (Humphries et al., 2004), while ﬂatworm FLPs
have been shown to signal mostly through phosphatidylinositol-
based pathways involving PLC and PKC (Graham et al., 2000;
Novozhilova et al., 2010). More speciﬁcally, a recent study showed
that the ﬂatworm FLP YIRFamide elicits its contractile effect on S.
mansoni dispersed muscle ﬁbres by indirect gating of sarcolemmal
voltage-operated Ca2+ channels, via a PKC-dependent pathway,
which is likely GPCR-mediated (Novozhilova et al., 2010). Similar
peptidergic signalling mechanisms in schistosomes may also in-
volve cytosolic liberation of sequestered intracellular Ca2+ from
the SR (Day et al., 2000). Conversely, nematode FLPs appear largely
to employ adenylate cyclase-mediated signalling pathways, where
the diverse FLP effects seen in A. suum or Ascaridia galli bioassays
are mediated by either upregulation or downregulation of cellular
cAMP levels (Trim et al., 1998; Reinitz et al., 2000; Thompson et al.,
2003). However, PKC-1 has also been implicated in the regulation
of C. elegans peptidergic secretion (Sieburth et al., 2007). An alter-
native, nitric oxide (NO)-based signalling mechanism is employed
by PF1 (SDPNFLRFamide), which relaxed A. suum somatic muscle
via nitric oxide synthase (NOS) activity within the hypodermis, a
Ca2+-dependent enzyme that catalyses production of the inhibitory
messenger, NO (Bowman et al., 1995; Bascal et al., 2001).
Several of the genes encoding components of these second mes-
senger pathways display mutant phenotypes related to viability or
reproductive function in both C. elegans and D. melanogaster (Ta-
ble 1). Current evidence suggests that adenylate cyclases may be
druggable, following description of an isoform-selective lead can-
didate inhibitor of mammalian adenylate cyclase AC1, which is
bioavailable in animal models following both oral and intraperito-
neal application (Wang et al., 2011). The isoform selectivity dem-
onstrated by this compound suggests that selective targeting of
parasite adenylate cyclase isoforms may be possible. Although
components of helminth second-messenger signal transduction
pathways appear to represent putative drug targets, knowledge
of the parasite homologues of these effectors is conspicuously
lacking.
4.3. Neuropeptide signal termination
Following activation of its cognate receptor(s), a neuropeptide
must be removed from the receptor’s binding site and cleared from
the synapse if further neurotransmission is to occur, in a process
designated signal termination. Neuropeptide signal termination is
performed by a battery of peptidases that may destroy peptides
either within the synaptic cleft, or following peptide/receptor
internalisation. The importance of the general process of signal
termination is well illustrated by the effects of carbamate-based
pesticides on AChEs, the signal terminating enzymes that destroysynaptic ACh and lead to paralysis and death in some pest species
(Baron, 1994).
Much neuropeptide breakdown in nematodes is seemingly per-
formed by neprilysin-like zinc metalloendopeptidases (Isaac et al.,
2000). C. elegans neprilysin knockouts display deleterious pheno-
types (Table 1; Spanier et al., 2005), although the speciﬁc synaptic
peptidolytic function of these mutants has not yet been examined.
Endopeptidase, aminopeptidase and deamidase activities have been
reported inA. suummuscle homogenates,where enzymes capable of
metabolising FLPs have been detected (Sajid and Isaac, 1994; Sajid
et al., 1996, 1997), and similar aminopeptidase activity capable of
digesting vertebrate peptide hormone substrates has been reported
in C. elegans and P. redivivus extracts (Masler, 2002). Comparative
studies are limited to the report of differential peptidolyticpotencies
between extracts of P. redivivus andM. incognita such that implica-
tions for selective chemotherapy or broad-spectrum utility of novel
drugs are unknown (Masler, 2010). The speciﬁc enzymes responsi-
ble for these activities have not yet been puriﬁed or cloned, although
evidence supports the involvement of a deamidase resembling
mammalian serine peptidase (Sajid and Isaac, 1994), a neprilysin-
like endopeptidase which does not appear to be membrane-bound
(Isaac et al., 2000), and an aminopeptidase with similar pharmacol-
ogy tomammalian aminopeptidase N (Sajid et al., 1997). Dipeptidyl
carboxypeptidase activity, common in other peptidergic signalling
systems, has not been described in nematodes (Isaac et al., 2000).
The employment of standard inhibitor proﬁling suggests that nem-
atode peptidases show both similarities and differences in their
pharmacology to that of orthologous vertebrate enzymes (Sajid
and Isaac, 1995; Sajid et al., 1996, 1997). Further studies will be re-
quired to identify helminth-speciﬁc inhibitors that might represent
novel drug lead candidates.5. Conclusions
Functional analyses of various components of helminth neurop-
eptidergic signalling systems indicate their potential utility as
targets for anthelmintic drugs. Despite this potential, the over-
whelming theme throughout this article is how little we still know
about the speciﬁc molecular players within parasitic helminths,
and how this currently inhibits our ability to test hypotheses relat-
ing to drug target validation. While C. elegans is a useful model for
many aspects of nematode biology, and has illuminated some struc-
tural and functional features of nematode neuropeptide pathways,
the species’ utility for elucidating neuropeptide function is limited
by poor knowledge of its relationship to parasitic forms, and by clear
differences in the complements of some proteins between C. elegans
and parasites. Nevertheless, nematode biology has had a head start
on ﬂatworm studies, where genome and transcriptome projects
have only recently appeared, and where we have yet to reap the
understanding of basic organismal and molecular biology enjoyed
by the C. elegans andD. melanogaster research communities. The po-
tential for exploitation of drug targets within helminth neuropep-
tide signalling has yet to be realised. With continued funding for
research into basic helminth neuropeptide biology, increased
knowledge can perhaps be translated into novel, broad spectrum
anthelmintics.Acknowledgements
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